Anebulo Pharmaceuticals Inc (ANEB)
1.84
-0.04
(-2.13%)
USD |
NASDAQ |
Nov 01, 16:00
Anebulo Pharmaceuticals Net Income (Quarterly): -1.35M for June 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | -1.35M |
March 31, 2024 | -1.654M |
December 31, 2023 | -2.717M |
September 30, 2023 | -2.481M |
June 30, 2023 | -2.496M |
March 31, 2023 | -2.798M |
December 31, 2022 | -3.827M |
September 30, 2022 | -2.612M |
Date | Value |
---|---|
June 30, 2022 | -2.323M |
March 31, 2022 | -1.876M |
December 31, 2021 | -1.073M |
September 30, 2021 | -1.553M |
June 30, 2021 | -29.11M |
March 31, 2021 | -0.5558M |
December 31, 2020 | -0.3286M |
September 30, 2020 | -0.2564M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-29.11M
Minimum
Jun 2021
-0.2564M
Maximum
Sep 2020
-3.563M
Average
-2.100M
Median
Net Income (Quarterly) Benchmarks
Revance Therapeutics Inc | -37.47M |
NovaBay Pharmaceuticals Inc | -1.585M |
Palatin Technologies Inc | -8.250M |
iBio Inc | -7.778M |
Theriva Biologics Inc | -8.316M |
Net Income (Quarterly) Related Metrics
Total Expenses (Quarterly) | 1.340M |
EPS Diluted (Quarterly) | -0.05 |
Enterprise Value | 44.62M |
Earnings Yield | -17.39% |